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Summary 
Using an in vivo test system, the role of the/31 integrin very late activation antigen-4 (VLA-4) 
in eosinophil accumulation i  allergic and nonallergic inflammatory eactions was investigated. 
Eosinophil infiltration and edema formation were measured asthe local accumulation f intravenously 
injected rain-labeled eosinophils and nSI-human serum albumin. The inflammatory reactions 
investigated were a passive cutaneous anaphylaxis (PCA) reaction and responses licited by intradermal 
soluble inflammatory mediators (platelet-activating factor, leukotriene B4, C5a des Arg), ara- 
chidonic acid, and zymosan particles. The in vitro pretreatment of mln-eosinophils with the 
anti-VLA-4 monoclonal ntibody (mAb) HP1/2, which crossreacts with guinea pig eosinophils, 
suppressed eosinophil accumulation i all the inflammatory eactions investigated. Eosinophil 
accumulation was inhibited to the same xtent when mAb HP1/2 was administered intravenously. 
It is interesting that HP1/2 had no effect on stimulated edema formation. These results uggest 
a role for VLA-4 in eosinophil accumulation i vivo and indicate a dissociation between the 
inflammatory events of eosinophil accumulation and edema formation. 
E osinophil accumulation is a prominent feature of allergic disorders, have elevated inflammatory Allergic patients 
levels of circulating eosinophils and these cells accumulate 
after antigenic hallenge in the skin, lungs, and nasal airways. 
Despite much research investigating the interaction of eo- 
sinophils with cultured endothelial cells, the mechanisms that 
mediate and control the accumulation ofeosinophils in vivo 
remain unclear. 
Adhesion of leukocytes to microvascular endothelium is
essential for their migration into inflamed tissues. This re- 
sponse is mediated by the interaction of adhesion molecules 
expressed on the cell surface of leukocytes and venular en- 
dothelial cells (1). The adherence of eosinophils to cultured 
endothelial cells has many functional and molecular charac- 
teristics similar to neutrophil-endothelial cell interaction. 
However, the recent demonstration that the r integrin 
VLA-4 (CD49d/CD29) is expressed on eosinophils and other 
leukocytes, but not the neutrophil, has led to suggestions 
that the VLA-4/VCAM-1 (vascular cell adhesion molecule 
1) adhesion pathway may be involved in specific eosinophil, 
as opposed to neutrophil, migration in vivo (2-4). This pro- 
posal has not, however, been directly addressed, and was the 
aim of the present investigation. 
Using an in vivo test system we have previously demon- 
strated the accumulation of eosinophils in guinea pig skin 
induced by preformed mediators CSa, leukotriene B4 (LTB4), 
and platelet-activating factor (PAF), and in a passive cuta- 
neous anaphylaxis (PCA) reaction (5, 6). In the present study, 
using this in vivo system we have investigated the effect of 
an anti-VLA-4 mAb on eosinophil accumulation. The results 
suggest that VLA-4 plays an important role in the accumula- 
tion of eosinophils in both allergic and nonallergic inflam- 
matory reactions. 
Materials and Methods 
Animals. Dunkin-Hartley guinea pigs (300-500 g) were pur- 
chased from Harlan Olac (Bicester, Oxon, UK). 
Reagents. PAF and LTB4 were obtained from Bachem (Buben- 
dorf, Switzerland) and Cascade Biochemical Ltd. (Berkshire, UK) 
respectively. Arachidonic acid (AA), zymosan, and bovine gamma 
globulin (BGG) were from Sigma Chemical Co. (Dorset, UK). 
nSI-human serum albumin (nSI-HSA) and mlndium chloride 
(mlnC13) were from Amersham International (Buckinghamshire, 
UK). Guinea pig zymosan-activated plasma (ZAP) was prepared 
as previously described and used as a source of CSa des Arg (5). 
mAbs. HP1/2 is a mouse IgG1 mAb directed to the c~4 chain 
(CD49d) of VLA-4 (7). The cell line was grown as an ascites, and 
mAb purified by protein A and gel filtration chromatography under 
endotoxin-free conditions. Endotoxin level of stock solution was 
assayed tobe 0.03 U/ml resulting in <0.005 U being injected into 
each animal. Isotype-matched mAb 1E6, generated to human LFA3, 
was used as a control antibody, mAb 1E6, purified as above, was 
a gift from Dr. W. Meier (Biogen Inc., Cambridge, MA). 
lmmunofluorescence FlowCytometry. Immunofluorescence flow 
cytometry was carried out based on a procedure previously described 
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(8). Briefly, horse serum-induced guinea pig peritoneal eosinophils 
or glycogen-induced peritoneal neutrophils (>98% pure) were sus- 
pended in Ca2*/Mg 2+ free HBSS (106/ml). Cell aliquots were 
treated with 10-500/~g/106 cells of mAb HP1/2 for 30 rain at 
4~ The cells were then washed twice in fresh HBSS and 
resuspended in buffer containing a saturating concentration f FITC 
rabbit anti-mouse antibody (Dako Ltd., Buckinghamshire, UK) 
for 30 rain at 4~ Finally, the cells were washed twice and ana- 
lyzed using a FACS | analyzer (Becton Dickinson & Co., Moun- 
tain View, CA) as previously reported (9). 
Measurement of m ln.eosinophil Accumulation a d Edema Formation 
in Guinea Pig Skin. mln-eosinophil accumulation and edema for- 
mation in guinea pig skin were simultaneously measured as previ- 
ously reported (5). Briefly, peritoneal eosinophils were induced by 
multiple intraperitoneal injections of horse serum. The eosinophils 
were purified over a discontinuous Percoll gradient yielding eosin- 
ophil preparations of95-100% purity. The cells were then radiola- 
beled with rain and finally injected intravenously in a volume of 
1 ml of HBSS containing 5 x 106-107 eosinophils mixed with 
nSI-HSA (5/~Ci/kg). 
In experiments investigating the effects of mAb HP1/2 or the 
control antibody, mAb 1E6, the rain-labeled eosinophils were 
divided into two aliquots, one of which was treated with the mAb 
(50/~g/106 cells) for 15 min at room temperature b fore the final 
wash. Alternatively, the antibodies were administered intravenously 
(3 mg/kg) with the radioisotopes. 
For the induction of a PCA reaction, animals were passively sen- 
sitized by intradermal injection of an IgGl-rich guinea pig anti- 
BGG antiserum (50/~1, 1:50 dilution) 20-24 h before the intrave- 
nous administration f radioisotopes a previously described (10). 
10 min after the intravenous injection of mln-eosinophils and mI- 
HSA, BGG was injected intradermally into sensitized sites and other 
stimuli (PAF, LTB4, ZAP, AA, and zymosan particles) were in- 
jected into naive sites. Each test was performed in duplicate sites 
according to a balanced site injection plan with an injection volume 
of 100/~l/site. After a 2-h in vivo period, a cardiac blood sample 
was collected and animals killed by an overdose of anaesthetic. The 
dorsal skin was then removed and skin sites punched out. The 
rain counts per eosinophil was determined and used to express eo- 
sinophil accumulation i each skin site in terms of the number of 
labeled leukocytes, corrected for 107 cells injected. Exudate 
volumes were expressed interms of microliters of plasma by dividing 
skin sample l~sI counts by 125I counts in 1/~1 of plasma. 
Statistical Analysis. Results are expressed as mean _+ SEM for 
n pairs of animals and have been analyzed for statistical significance 
using a paired two-way Student's t test. A p value of <0.05 was 
considered statistically significant. 
Results 
Immunofluorescence FlowCytometry. Guinea pig eosinophils 
bound HP1/2 with a saturating concentration of 50/.tg/106 
cells. At this concentration, mAb HP1/2 did not bind to 
guinea pig neutrophils (Fig. 1). Based on these results, HP1/2 
was used at the concentration of 50 #g/106 cells to pretreat 
mIn-eosinophils in vitro for the in vivo experiments de- 
scribed below. 
Effect of mAb HPI/2 on mln-Eosinophil Accumulation and 
Edema Formation I duced by Exogenous Inflammatory Mediators, 
AA, and Zymosan Particles. Intradermal injections of PAF, 
LTB4, and guinea pig ZAP induced ntln-eosinophil accumu- 
lation over the 2-h test period in guinea pig skin (Figs. 2 
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Figure 1. Flow cytometry of guinea pig eosinophils and neutrophils 
stained with mAb HP1/2. Cells were incubated with mAb HP1/2 at 50 
#g/106 cells followed by staining with a FITC anti-mouse antibody as 
described in Materials and Methods. (Broken lines) Nonspecific binding; 
(solid lines) specific binding. 
and 3). LTB4 was found to be more potent than PAF in in- 
ducing eosinophil accumulation with little edema, whilst PAF 
was very effective in inducing edema. 
The in vitro pretreatment of mln-eosinophils with mAb 
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Figure 2. 
edema formation i duced by intradermal injections of PAF and LTB4. P~- 
diolabeled eosinophils were untreated (control) or pretreated with mAb 
HP1/2 at a concentration f 50/~g/106 cells before their final wash and 
intravenous injection into recipient guinea pigs. Results are the mean + 
SEM for n = 3-8 pairs of guinea pigs. (*) Significant difference from 
control, p <0.05. 
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Effect of pretreatment of cells with mAb HP1/2 on rain- 
eosinophil w.cumulation induced by intradermal guinea pig ZAE See legend 
to Fig. 2 for details. Results are the mean +- SEM for n = 9 pairs of 
guinea pigs. (*) Significant difference from control, p <0.05. 
HP1/2 almost completely inhibited their accumulation i re- 
sponse to PAF and LTB4 (Fig. 2), whilst partially inhibiting 
the response to ZAP (Fig. 3). This procedure also inhibited 
ltqn-eosinophil accumulation i duced by intradermal AA 
and zymosan particles (Fig. 4). It is interesting that the small 
level of eosinophil accumulation detected in sites injected with 
saline/BSA was also significantly inhibited. Edema forma- 
tion in animals receiving treated cells was not significantly 
different from the responses in guinea pigs injected with con- 
trol 111In-eosinophils (Fig. 2 for PAF and LTB4; data not 
shown for other stimuli). 
mAb HP1/2 had similar inhibitory effects on mln- 
eosinophil accumulation, but not edema formation, when 
it was administered intravenously at 3 mg/kg (Table 1 and 
Fig. 4). Preliminary experiments demonstrated that increasing 
the dose to 10 mg/kg did not enhance the inhibitory effect 
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Effect of mAb HP1/2 on mln-eosinophil accumulation i - Figure 4. 
duced by intradermal AA and zymosan particles. Guinea pigs received con- 
trol untreated mln-eosinophils, HP1/2 in vitro pretreated mln-eosinophils 
(50/zg/106 cells) or mln-eosinophils coinjected with HP1/2 (3 mg/kg 
i.v.). Arachidonic acid (AA) and zymosan particles were injected intrader- 
mally 10 rain after the intravenous injection of radiolabehd cells and 12sI- 
HSA. Results are the mean +_ SEM for n = 4-8 pairs of guinea pigs. 
(*) Significant difference from control, p <0.05. 
of HP1/2, whilst I mg/kg gave a greatly reduced inhibition 
of cell accumulation. 
The inhibitory effect ofmAb HP1/2 was not due to a reduc- 
tion in the number of circulating radiolabeled leukocytes in 
the guinea pigs, e.g., percentage ofcontrol abeled eosinophils 
and mAb HP1/2-treated nlln-eosinophils circulating at the 
end of the 2-h in vivo test period were 10.3 _+ 3.1% and 
7.0 _+ 2.7% (percent injected cells; mean _+ SEM, n = eight 
pairs of animals), respectively. Pretreatment of labeled eo- 
sinophils with a control mouse IgG (mAb 1E6) or the intra- 
venous administration f mAb 1E6, did not significantly affect 
Utln-eosinophil accumulation, e.g., with intravenous 1E6, 
percent changes in mln-eosinophil accumulation over un- 
Table 1. Effect of Intravenous mAb HP1/2 on "lln-eosinophil Accumulation a d Edema Formation Induced by 
Inflammatory Mediators 
mln-eosinophils/site ( x 10 3) /A Plasma 
Intravenous Intravenous 
Control HP1/2 Control HP1/2 
Saline/0.1% BSA 1.02 _+ 0.29 0.4 _+ 0.07" 16.23 -+ 3.66 16.65 ,+ 6.52 
LTB4 (5 x 10 -1~ mol/site) 3.07 _+ 0.84 1.61 _+ 0.48" 20.38 _+ 2.51 19.04 ,+ 2.27 
PAF (10 -9 tool/site) 6.45 _+ 2.27 1.86 + 0.35" 94.70 _+ 21.64 90.53 ,+ 17.0 
ZAP (100%) 19.79 ,+ 3.25 8.75 _+ 2.0* 44.35 _+ 8.64 52.65 ,+ 7.32 
mAb HP1/2 was administered intravenously 0 mg/kg) 10 rain before intradermal dministration fLTB4, PAF, and ZAP. tllIn-eosinophil accumu- 
lation and edema formation in guinea pig skin were measured over a 2-h in vivo test period as described in Materials and Methods. Results are 
mean :t: SEM for n = 4-5 pairs of animals. 
* p <0.05, a significant difference from control. 
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Figure 5. Effect of mAb HP1/2 pretreatment on mln-eosinophil ac- 
cumulation in the PCA reaction. To didt the PCA reaction, antigen (BGG) 
was administered intradermaUy into previously sensitized sites. Control 
skin sites injected with BGG or antisera (AS) alone were also included. 
Radiolabeled eosinophils were untreated (control) or pretreated with mAb 
HP1/2 at a concentration of 50/tg/10~ cells before their final wash and 
intravenous injection into recipient guinea pigs. Results are the mean _+ 
SEM for n = 4-6 pairs of animals. (*) Significant difference from contrd, 
p <0.05. 
treated cells were 22.3 • 19.3% and 10.6 • 26.4% (n = 
four pairs) for PAF and LTB4, respectively. 
Effect of mAb HP1/2 on l" In-Eosinophil Accumulation i  the 
PCA Reaction. Injection of antigen (BGG) into sensitized 
sites led to a marked and dose-dependent lltln-eosinophil ac- 
cumulation i the guinea pig skin, whilst BGG and antisera 
injected alone induced very small responses (Fig. 5). 
As observed with the exogenous mediators, AA and 
zymosan particles, the in vitro pretreatment of ttlln- 
eosinophils with mAb HP1/2 significantly inhibited their ac- 
cumulation i  the PCA reaction. HP1/2 also inhibited the 
small cell accumulation induced by BGG and antisera where 
small inflammatory esponses were possibly induced. 
Discussion 
Eosinophils have been implicated in the pathogenesis of 
a wide variety of inflammatory disease states including al- 
lergic disorders. The mechanisms that mediate and regulate 
the selective accumulation f eosinophils in sites of allergic 
inflammation remain undear. Both neutrophils and eosinophils 
respond to chemoattractants such as C5a, LT84, and PAF 
and exhibit enhanced adhesion to cytokine-activated en othelial 
cells in a CD18-dependent manner (11, 12). Intercellular dhe- 
sion molecule 1(ICAM-1), an important ligand for CDlla/ 
CD18 and CDllb/CD18 (13-15) has been shown to be in- 
volved in neutrophil and eosinophil adhesion i  vitro (15-17) 
and accumulation i  vivo (18, 19). E-selectin has also been 
implicated in neutrophil and eosinophil adhesion to cytokine- 
activated endothelial cells in vitro (2, 16, 17), however, of 
the two leukocyte types, only eosinophils express VLA-4 that 
binds to VCAM-1 on activated endothelial cells (2-4). The 
characterization f the VLA-4/VCAM-1 adhesion pathway 
has led to suggestions that this interaction may mediate the 
accumulation f eosinophils, as opposed to neutrophils, into 
sites of eosinophilic nflammation. In the present study using 
a neutralizing anti-VLA-4 mAb, which blocks both VLA-4/ 
VCAM-1 and VLA-4/fibronectin i teractions (7), we have 
demonstrated a role for VLA-4 in eosinophil accumulation 
in vivo. 
Intradermal chemoattractants PAF, LTB4, and C5a des 
Arg (in ZAP) induced eosinophil accumulation in guinea pig 
skin which was inhibited by mAb HP1/2, whether used to 
pretreat the mln-eosinophils in vitro or given intravenously. 
These chemoattractants, which do not appear to activate n- 
dothelial cells, are believed to stimulate osinophil adhesion 
in the venule lumen primarily by a CD18-dependent mecha- 
nism. It was therefore interesting to observe that an anti- 
VLA-4 mAb inhibited eosinophil accumulation i duced by 
these mediators, although other workers have shown that 
VLA-4 is not upregulated bya chemoattractant such as PAF 
and the antibody does not inhibit eosinophil adherence in
vitro to endothelial cells induced by PAF (3). Whilst HP1/2 
almost completely inhibited the responses induced by PAF 
and LTB4, it only partially suppressed eosinophil accumula- 
tion induced by C5a des Arg. These findings indicate that 
VLA-4 plays an important role in chemoattractant-induced 
eosinophil accumulation in vivo, but other VLA-4-indepen- 
dent adhesion pathways perhaps involving CD18 and ICAM-1 
may also be involved in eosinophil accumulation induced by 
C5a des Arg. HP1/2 also inhibited eosinophil accumulation 
induced by the endogenous generation of mediators in re- 
sponse to AA, zymosan, and in PCA reactions. However, 
in no case was inhibition of edema formation seen when using 
HP1/2. These findings indicate a dissociation between the 
inflammatory events of eosinophil accumulation a d plasma 
protein leakage. Edema formation induced by chemoattrac- 
rants in this model, as found in other in vivo models (20, 
21), may be mediated by the process of neutrophil accumu- 
lation. 
Although in vitro studies have shown that VLA-4 can in- 
teract with VCAM-1 (22), fibronectin (23), and a ligand in- 
volved in leukocyte homotypic aggregation (7), the existence 
of as yet uncharacterized VLA-4 ligands is strongly suggested 
(7, 24). In the present in vivo study, whilst demonstrating 
an important role for VLA-4 in eosinophil accumulation, we 
have not attempted to identify the possible ligands with which 
VLA-4 may be interacting. A possible candidate is clearly 
VCAM-1, which may be basally expressed on venular en- 
dothelial cells in vivo. In addition, upregulation fVCAM-1 
expression i vivo may be involved. Time course xperiments 
with cytokine-activated cultured endothelial cells have shown 
that significant levels of VCAM-1 can be detected as early 
as 1-2 h, though expression peaks after 6-10 h of cytokine 
treatment (25, 26). It is possible that induction of VCAM-1 
is faster on venular endothelial cells in vivo to account for 
the rapid appearance of eosinophils. The availability of mAbs 
to guinea pig VCAM-1 will allow us to investigate directly 
the involvement ofthis molecule in eosinophil accumulation 
in our in vivo model and to determine the time course of 
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VCAM-1 expression within skin sites by immunohistology. 
In addition, whilst numerous tudies have investigated the 
interaction of VLA-4 with VCAM-1 with respect o leukocyte- 
endothelial cell adhesion, very few have addressed the involve- 
ment of this adhesion pathway in the process of leukocyte 
transendothelial cell migration. VLA-4 may interact with a 
different ligand to VCAM-1 during this process. Clearly, fur- 
ther in vivo studies are required to dissect he involvement 
of endothelial cell adhesion molecules in the process of eo- 
sinophil accumulation i vivo. The interaction of VLA-4 with 
fibronectin may also partly explain the present results. 
Fibronectin can be deposited on the lumenal surface of the 
endothelium at sites of skin inflammation (27), and its inter- 
action with circulating leukocytes may contribute to the pro- 
cess of leukocyte migration in vivo (28). 
In summary, the results presented here strongly indicate 
a role for VLA-4 in the process of eosinophil accumulation 
in both allergic and nonallergic inflammatory reactions. Al- 
though the ligands with which VLAo4 is interacting in vivo 
are yet to be determined, our findings suggest hat VLA-4 
blockers may be highly effective therapeutic tools in the treat- 
ment of inflammatory conditions where eosinophil accumu- 
lation is a prominent feature. 
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